XEOMIN Is a Unique First-line Neuromodulator Therapy for Your Adult Patients With:
-Upper limb spasticity
XEOMIN is a clinically proven therapy that’s helped more than 3 million patients in over 70 countries worldwide for various conditions. That number continues to grow
Xeomin has available outside the US since 2005 and was introduced in the US in 2010. Xeomin was given FDA approval in July 2011 for the treatment of cervical dystonia, blepharospasm, and glabellar lines, but an injuction halted the release. Now, after a 10-month injunction, Xeomin is again being launched in the US as a treatment of glabellar lines. Xeomin®, by Merz Pharmaceuticals LLC, is a competitor to the well established Botox Cosmetic® and lesser-used Dysport®.
Patients are less likely to become resistant to Xeomin because there are simply fewer ingredients in the solution. Some patients have developed antibodies to Botox and Dysport.